Growth Inhibition and Cell Cycle Arrest of Kappa-Selenocarrageenan and Paclitaxel on HepG2 Cells

被引:0
作者
Ling, Na [1 ]
机构
[1] Harbin Univ Commerce, Life Sci & Environm Sci Res Ctr, Harbin, Heilongjiang Pr, Peoples R China
来源
MATERIALS FOR ENVIRONMENTAL PROTECTION AND ENERGY APPLICATION, PTS 1 AND 2 | 2012年 / 343-344卷
关键词
Kappa-selenocarrageenan; paclitaxel; hepG2; cells; combination; cell cycle; CANCER PREVENTION; SELENIUM; TAXOL; SUPPLEMENTATION; CARCINOMA; TRIAL;
D O I
10.4028/www.scientific.net/AMR.343.344.530
中图分类号
TE [石油、天然气工业]; TK [能源与动力工程];
学科分类号
0807 ; 0820 ;
摘要
To evaluate the anti-proliferative effect of kappa-selenocarrageenan (KSC) in combination with paclitaxel (Taxol) on human hepatoma cell line HepG2 and their synergistic effect. The cytotoxic effect of drugs on HepG2 cells was measured by MTT assay, and the King's principle was used to evaluate the interaction of drug combination. Cell cycle and apoptotic rate were detected by flow cytometry (FCM). Expression of cyclin A, chk2, Cdc25A and cdk2 were detected by flow cytometry and western blotting. KSC and Taxol demonstrated growth inhibitory effect on HepG2 cells in a dose-dependent manner, with the IC50 values of Taxol decreased dramatically from 1.684 nmol/L to 0.272 nmol/L while combining with 30 mg/L KSC (P<0.01). In addition, additive activity was observed when 30 mg/L KSC was combined with Taxol (0.5 similar to 5 nmol/L) (q=0.85 similar to 1.15). FCM results showed that KSC and Taxol both blocked cell cycle in S phase and their combination enhanced S phase arrest. Western blotting analysis revealed that Cyclin A and chk2 protein expression in HepG2 cells increased but Cdc25A and cdk2 expression decreased.
引用
收藏
页码:530 / 534
页数:5
相关论文
共 16 条
  • [1] BUZDAR AU, 1995, SEMIN ONCOL, V22, P101
  • [2] Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin a randomized controlled trial - A randomized controlled trial
    Clark, LC
    Combs, GF
    Turnbull, BW
    Slate, EH
    Chalker, DK
    Chow, J
    Davis, LS
    Glover, RA
    Graham, GF
    Gross, EG
    Krongrad, A
    Lesher, JL
    Park, HK
    Sanders, BB
    Smith, CL
    Taylor, JR
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1996, 276 (24): : 1957 - 1963
  • [3] DONEHOWER RC, 1987, CANCER TREAT REP, V71, P1171
  • [4] Paclitaxel shows cytotoxic activity in human hepatocellular carcinoma cell lines
    Gagandeep, S
    Novikoff, PM
    Ott, M
    Gupta, S
    [J]. CANCER LETTERS, 1999, 136 (01) : 109 - 118
  • [5] Selenium metabolism, selenoproteins and mechanisms of cancer prevention: complexities with thioredoxin reductase
    Ganther, HE
    [J]. CARCINOGENESIS, 1999, 20 (09) : 1657 - 1666
  • [6] He G, 1997, Zhonghua Yu Fang Yi Xue Za Zhi, V31, P103
  • [7] The protective role of selenium on the toxicity of cisplatin-contained chemotherapy regimen in cancer patients
    Hu, YJ
    Chen, Y
    Zhang, YQ
    Zhou, MZ
    Song, XM
    Zhang, BZ
    Luo, L
    Xu, PM
    Zhao, YN
    Zhao, YB
    Cheng, G
    [J]. BIOLOGICAL TRACE ELEMENT RESEARCH, 1997, 56 (03) : 331 - 341
  • [8] Jin Z.J., 1980, ZHONGGUO YAO LI XUE, V1, P70
  • [9] Lin Z. J., 1993, TRACE ELEMENT ANAL A, P34
  • [10] Ling N., 2009, ASIA PACIFIC TRADITI, V5, P13